Physician profile
Darpan Bansal
NPI 1659567816
$7,807.76
in general payments reported to CMS, 2019-2025
35 companies · $760 in 2025
The $760 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,195 · 2020: $353 · 2021: $780 · 2022: $1,471 · 2023: $1,900 · 2024: $1,349 · 2025: $760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,008.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,007.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,960.03 | 2019-2025 | Dragonfly Opstar, Xience Skypoint, Nc Trek Neo |
| Novartis Pharmaceuticals Corporation | $910.69 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $667.15 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $632.89 | 2019-2025 | Jardiance |
| Pfizer INC. | $449.11 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $432.81 | 2021-2025 | Verquvo |
| Medtronic Vascular, INC. | $390.26 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $309.06 | 2019-2025 | Farxiga, Brilinta |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $283.58 | 2019-2025 | Lifevest |
| Alnylam Pharmaceuticals INC. | $227.42 | 2022-2025 | Amvuttra, Onpattro |
| Sanofi-Aventis U.S. LLC | $175.94 | 2019-2022 | |
| Medtronic, INC. | $173.26 | 2022-2024 | Azure Xt Dr Mri Surescan |
| Amgen INC. | $169.04 | 2019-2023 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $158.68 | 2021-2025 | Camzyos |
| Atricure, INC. | $148.93 | 2023 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $91.84 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Kiniksa Pharmaceuticals International, Plc | $86.23 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $61.65 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $61.28 | 2022-2023 | Arcalyst |
| Amarin Pharma, INC. | $46.27 | 2019-2020 | |
| Scpharmaceuticals INC. | $40.75 | 2023-2025 | |
| Abiomed | $38.26 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $37.28 | 2023 | Opsumit |
| Watermark Medical, INC. | $33.26 | 2024 | |
| Cleerly, INC. | $29.35 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Arbor Pharmaceuticals, INC. | $28.41 | 2019-2020 | |
| Preventice Services, LLC | $23.85 | 2019 | |
| Philips North America LLC | $21.74 | 2024 | (Cm9) Amb Mon & Diag Und |
| Edwards Lifesciences Corporation | $21.52 | 2023 | Hemosphere |
| Lexicon Pharmaceuticals, INC. | $18.71 | 2024 | |
| Lantheus Medical Imaging, INC. | $18.23 | 2021 | |
| Irhythm Technologies, INC. | $16.05 | 2019 | |
| Terumo Medical Corporation | $15.78 | 2024 | Tr Band |
| Glaxosmithkline, LLC. | $15.22 | 2025 | Shingrix, Arexvy |
| Boston Scientific Corporation | $13.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darpan Bansal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.